Profile data is unavailable for this security.
About the company
Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.
- Revenue in USD (TTM)0.00
- Net income in USD-5.30m
- Incorporated2020
- Employees4.00
- LocationVirios Therapeutics Inc44 Milton AvenueALPHARETTA 30009United StatesUSA
- Websitehttps://www.virios.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pasithea Therapeutics Corp | 0.00 | -15.51m | 7.43m | 8.00 | -- | 0.3174 | -- | -- | -12.83 | -13.18 | 0.00 | 22.46 | 0.00 | -- | -- | 0.00 | -43.50 | -- | -46.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -28.74m | 7.50m | 38.00 | -- | -- | -- | -- | -0.6324 | -0.6324 | 0.00 | -0.0241 | 0.00 | -- | -- | 0.00 | -284.51 | -- | -- | -- | -- | -- | -- | -- | -- | -25.25 | 1.25 | -- | -89.98 | -- | -132.57 | -- | -- | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -48.93m | 7.55m | 22.00 | -- | 1.19 | -- | -- | -12.41 | -12.41 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -124.91 | -61.43 | -150.17 | -68.82 | -- | -- | -- | -- | -- | -4,784.14 | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Trevena Inc | 3.13m | -40.29m | 7.64m | 23.00 | -- | -- | -- | 2.44 | -3.16 | -3.16 | 0.2611 | -0.4429 | 0.07 | 3.69 | -- | 135,869.60 | -90.25 | -55.93 | -110.38 | -66.35 | 46.56 | -- | -1,289.25 | -3,134.41 | 4.66 | -15.43 | 1.33 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Azitra Inc | 686.00k | -12.64m | 7.67m | 10.00 | -- | 1.11 | -- | 11.18 | -2.99 | -2.99 | 0.0713 | 0.2408 | 0.1117 | -- | 4.88 | 68,600.00 | -183.73 | -- | -266.83 | -- | -- | -- | -1,644.87 | -- | -- | -45.86 | 0.0138 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
| Cyclerion Therapeutics Inc | 0.00 | -12.59m | 7.70m | 1.00 | -- | 0.6225 | -- | -- | -5.22 | -2.29 | 0.00 | 4.56 | 0.00 | -- | -- | 0.00 | -80.08 | -72.70 | -115.85 | -86.96 | -- | -- | -- | -2,565.62 | -- | -- | 0.00 | -- | -100.00 | -- | 30.98 | -- | -- | -- |
| CV Sciences Inc | 16.00m | 3.10m | 7.83m | 42.00 | 2.33 | 2.67 | 2.35 | 0.4894 | 0.0206 | 0.0206 | 0.104 | 0.018 | 1.46 | 1.46 | 26.74 | 381,047.60 | 28.28 | -43.42 | 247.47 | -77.75 | 44.27 | 51.81 | 19.38 | -45.68 | 0.3733 | 13.68 | 0.0805 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
| Virios Therapeutics Inc | 0.00 | -5.30m | 7.90m | 4.00 | -- | -- | -- | -- | -0.283 | -0.283 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
| Cadrenal Therapeutics Inc | -100.00bn | -100.00bn | 8.00m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Longeveron Inc | 709.00k | -22.21m | 8.06m | 23.00 | -- | 3.96 | -- | 11.37 | -10.18 | -10.18 | 0.3262 | 0.4245 | 0.0359 | -- | 4.31 | 30,826.09 | -108.45 | -63.15 | -139.35 | -75.68 | 31.17 | 33.70 | -3,020.17 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| NuCana PLC (ADR) | 0.00 | -34.71m | 8.20m | 25.00 | -- | 0.4387 | -- | -- | -412.56 | -412.56 | 0.00 | 8.84 | 0.00 | -- | -- | 0.00 | -64.21 | -41.01 | -102.19 | -48.07 | -- | -- | -- | -- | -- | -77.43 | 0.0259 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
| Paranovus Entertainment Technology Ltd | 51.46m | -42.62m | 8.22m | 80.00 | -- | 0.7696 | -- | 0.1597 | -7.16 | -7.49 | 9.89 | 1.46 | 1.18 | 59.61 | 4.15 | 643,209.90 | -91.12 | -23.19 | -119.36 | -27.21 | 4.92 | 23.09 | -77.15 | -24.25 | 3.97 | -2,465.22 | 0.00 | -- | 9.68 | 9.80 | -45.84 | -- | -21.93 | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 8.31m | 389.00 | 0.0015 | 0.0002 | 0.9003 | 0.1459 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 260.50k | -19.03m | 8.36m | 8.00 | -- | 0.7269 | -- | 32.07 | -3.62 | -3.62 | 0.0489 | 1.77 | 0.0132 | -- | 13.06 | 32,562.50 | -96.49 | -66.49 | -117.79 | -85.55 | -- | -- | -7,304.76 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
Data as of May 07 2024. Currency figures normalised to Virios Therapeutics Inc's reporting currency: US Dollar USD
4.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 208.88k | 1.09% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 206.70k | 1.07% |
| Geode Capital Management LLCas of 31 Dec 2023 | 174.47k | 0.91% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 52.83k | 0.27% |
| McCollum Christoferson Group LLCas of 31 Mar 2024 | 42.00k | 0.22% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Mar 2024 | 30.00k | 0.16% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 24.04k | 0.13% |
| XTX Markets LLCas of 31 Dec 2023 | 22.76k | 0.12% |
| Regions Investment Management, Inc.as of 31 Mar 2024 | 20.07k | 0.10% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 15.00k | 0.08% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
